The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrum
Open accessAbstract
Somatic mutations in the phosphatidylinositol/AKT/mTOR pathway cause segmental overgrowth disorders. Diagnostic descriptors associated with PIK3CA mutations include fibroadipose overgrowth (FAO), Hemihyperplasia multiple Lipomatosis (HHML), Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, Scoliosis/skeletal and spinal (CLOVES) syndrome, macrodactyly, and the megalencephaly syndrome, Megalencephaly‐Capillary malformation (MCAP) syndrome. We set out to refine the understanding of the clinical spectrum and natural history of these phenotypes, and now describe 35 patients with segmental overgrowth and somatic PIK3CA mutations. The phenotypic data show that these previously described disease entities have considerable overlap, and represent a spectrum. While this spectrum overlaps with Proteus syndrome (sporadic, mosaic, and progressive) it can be distinguished by the absence of cerebriform connective tissue nevi and a distinct natural history. Vascular malformations were found in 15/35 (43%) and epidermal nevi in 4/35 (11%) patients, lower than in Proteus syndrome. Unlike Proteus syndrome, 31/35 (89%) patients with PIK3CA mutations had congenital overgrowth, and in 35/35 patients this was asymmetric and disproportionate. Overgrowth was mild with little postnatal progression in most, while in others it was severe and progressive requiring multiple surgeries. Novel findings include: adipose dysregulation present in all patients, unilateral overgrowth that is predominantly left‐sided, overgrowth that affects the lower extremities more than the upper extremities and progresses in a distal to proximal pattern, and in the most severely affected patients is associated with marked paucity of adipose tissue in unaffected areas. While the current data are consistent with some genotype–phenotype correlation, this cannot yet be confirmed. © The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ
Shirley, M. D., Tang, H., Gallione, C. J., Baugher, J. D., Frelin, L. P., Cohen, B., North, P. E., Marchuk, D. A., Comi, A. M., & Pevsner, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213507 · Cited by 1,096
Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene
Chen, W. S., Xu, P.-Z., Gottlob, K., Chen, M.-L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. (2001) · Genes & Development · doi:10.1101/gad.913901 · Cited by 928
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome
Lindhurst, M. J., Sapp, J. C., Teer, J. K., Johnston, J. J., Finn, E. M., Peters, K., Turner, J., Cannons, J. L., Bick, D., Blakemore, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104017 · Cited by 903
Self-citationPhosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
Finding of Rare Disease Genes (FORGE) Canada Consortium, Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2331 · Cited by 741
Self-citationDe novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
Lee, J. H., Huynh, M., Silhavy, J. L., Kim, S., Dixon-Salazar, T., Heiberg, A., Scott, E., Bafna, V., Hill, K. J., Collazo, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2329 · Cited by 703
Role of Akt/protein kinase B in metabolism
Whiteman, E. L., Cho, H., & Birnbaum, M. J. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00662-8 · Cited by 676
Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome
Kurek, K. C., Luks, V. L., Ayturk, U. M., Alomari, A. I., Fishman, S. J., Spencer, S. A., Mulliken, J. B., Bowen, M. E., Yamamoto, G. L., Kozakewich, H. P. W., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.05.006 · Cited by 532
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 506
Somatic activation of AKT3 causes hemispheric developmental brain malformations
Poduri, A., Evrony, G. D., Cai, X., Elhosary, P. C., Beroukhim, R., Lehtinen, M. K., Hills, L. B., Heinzen, E. L., Hill, A., Hill, R. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.010 · Cited by 478
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4114 · Cited by 369
The prevalence of PIK3CA mutations in gastric and colon cancer
Velho, S., Oliveira, C., Ferreira, A., Ferreira, A. C., Suriano, G., Schwartz, S., Duval, A., Carneiro, F., Machado, J. C., Hamelin, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.022 · Cited by 341
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Lindhurst, M. J., Parker, V. E. R., Payne, F., Sapp, J. C., Rudge, S., Harris, J., Witkowski, A. M., Zhang, Q., Groeneveld, M. P., Scott, C. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2332 · Cited by 325
Self-citationMirzaa, G. M., Conway, R. L., Gripp, K. W., Lerman‐Sagie, T., Siegel, D. H., deVries, L. S., Lev, D., Kramer, N., Hopkins, E., Graham, J. M., et al. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.34402 · Cited by 240
Self-citationKinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 214
Hafner, C., López-Knowles, E., Luis, N. M., Toll, A., Baselga, E., Fernández-Casado, A., Hernández, S., Ribé, A., Mentzel, T., Stoehr, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705218104 · Cited by 209
An Activating Mutation of AKT2 and Human Hypoglycemia
Hussain, K., Challis, B., Rocha, N., Payne, F., Minic, M., Thompson, A., Daly, A., Scott, C., Harris, J., Smillie, B. J. L., et al. (2011) · Science · doi:10.1126/science.1210878 · Cited by 178
Self-citationMegalencephaly Syndromes and Activating Mutations in the PI3K‐AKT Pathway: MPPH and MCAP
MIRZAA, G. M., RIVIÈRE, J., & DOBYNS, W. B. (2013) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31361 · Cited by 172
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly
Rios, J. J., Paria, N., Burns, D. K., Israel, B. A., Cornelia, R., Wise, C. A., & Ezaki, M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds440 · Cited by 168
Cohen, M. M. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20000731)93:3<171::aid-ajmg1>3.0.co;2-k · Cited by 165
Mutations of PIK3CAin gastric adenocarcinoma
Li, V. S. W., Wong, C. W., Chan, T. L., Chan, A. S. W., Zhao, W., Chu, K.-M., So, S., Chen, X., Yuen, S. T., & Leung, S. Y. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-29 · Cited by 164
Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation
Adams, J. R., Xu, K., Liu, J. C., Agamez, N. M. R., Loch, A. J., Wong, R. G., Wang, W., Wright, K. L., Lane, T. F., Zacksenhaus, E., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0738 · Cited by 163
Rapamycin treatment for a child with germline PTEN mutation
Marsh, D. J., Trahair, T. N., Martin, J. L., Chee, W. Y., Walker, J. L., Kirk, E. P., Baxter, R. C., & Marshall, G. M. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1112 · Cited by 143
Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors
Meyer, D. S., Brinkhaus, H., Müller, U., Müller, M., Cardiff, R. D., & Bentires‐Alj, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3827 · Cited by 125
Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
Cizkova, M., Dujaric, M. E., Lehmann‐Che, J., Scott, V., Tembo, O., Asselain, B. J. R., Pierga, J., Marty, M. E., de Crémoux, P., Spyratos, F., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.164 · Cited by 92
Lu, P., Minowada, G., & Martin, G. R. (2005) · Development · doi:10.1242/dev.02172 · Cited by 91
Novel AKT1-GLI3-VMP1 Pathway Mediates KRAS Oncogene-induced Autophagy in Cancer Cells
Lo Ré, A. E., Fernández-Barrena, M. G., Almada, L. L., Mills, L. D., Elsawa, S. F., Lund, G., Ropolo, A., Molejon, M. I., Vaccaro, M. I., & Fernandez-Zapico, M. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.370809 · Cited by 87
Next generation sequencing--implications for clinical practice
Raffan, E., & Semple, R. K. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr029 · Cited by 68
Self-citationCLOVES syndrome with thoracic and central phlebectasia: Increased risk of pulmonary embolism
Alomari, A. I., Burrows, P. E., Lee, E. Y., Hedequist, D., Mulliken, J. B., & Fishman, S. J. (2010) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.04.023 · Cited by 63
PIK3CA-Related Segmental Overgrowth
Mirzaa, G., Conway, R. L., Graham, J. M., & Dobyns, W. B. (2013) · Europe PMC (PubMed Central) · Cited by 50
Self-citationAssessment and management of the orthopedic and other complications of Proteus syndrome
Tosi, L. L., Sapp, J. C., Allen, E. S., O’Keefe, R. J., & Biesecker, L. G. (2011) · Journal of Children s Orthopaedics · doi:10.1007/s11832-011-0350-6 · Cited by 37
Self-citationBouldin, C. M., & Harfe, B. D. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.07.009 · Cited by 27
Aspirin,PIK3CAMutation, and Colorectal-Cancer Survival
Ogino, S., Liao, X., & Chan, A. T. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1214189 · Cited by 15
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S., Duong, J.-P., Blanc, E., Johnson, S. C., Hoguin, C., Boccara, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0217-9 · Cited by 589
Keppler‐Noreuil, K. M., Rios, J. J., Parker, V. E. R., Semple, R. K., Lindhurst, M. J., Sapp, J. C., Alomari, A., Ezaki, M., Dobyns, W., & Biesecker, L. G. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36836 · Cited by 580
Self-citationJansen, L. A., Mirzaa, G. M., Ishak, G. E., O'Roak, B. J., Hiatt, J. B., Roden, W. H., Gunter, S. A., Christian, S. L., Collins, S., Adams, C., et al. (2015) · Brain · doi:10.1093/brain/awv045 · Cited by 364
Somatic Activating PIK3CA Mutations Cause Venous Malformation
Limaye, N., Kangas, J., Mendola, A., Godfraind, C., Schlögel, M. J., Helaers, R., Eklund, L., Boon, L. M., & Vikkula, M. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.11.011 · Cited by 351
Metadata
- Authors
- Keppler‐Noreuil, K. M., Sapp, J. C., Lindhurst, M. J., Parker, V. E. R., Blumhorst, C., Darling, T., Tosi, L. L., Huson, S. M., Whitehouse, R. W., Jakkula, E., Grant, I., Balasubramanian, M., Chandler, K. E., Fraser, J. L., Gucev, Z., Crow, Y. J., Brennan, L. M., Clark, R., Sellars, E. A., Pena, L. D., Krishnamurty, V., Shuen, A., Braverman, N., Cunningham, M. L., Sutton, V. R., Tasic, V., Graham, J. M., Geer, J., Henderson, A., Semple, R. K., & Biesecker, L. G.
- Venue
- American Journal of Medical Genetics Part A
- Publisher
- Wiley
- Published
- 2014-04-29
- Volume
- 164
- Issue
- 7
- Pages
- 1713-1733
- ISSN
- 1552-4825 (ISSN-L)
- 1552-4833
- OpenAlex
- W1988673699
- Cited by
- 305
- References
- 39
- FWCI
- 22.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.